Adicet Bio, Inc. (NASDAQ:ACET)
| Market Cap | 59.36M-52.2% |
| Revenue (ttm) | 0 |
| Net Income | -98.97M+16.6% |
| EPS | -11.45+45.4% |
| Shares Out | 9.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Sep 21, 2018 |
| Volume | 2,129,093 |
| Open | 7.78 |
| Previous Close | 9.02 |
| Day's Range | 6.25 - 7.96 |
| 52-Week Range | 6.01 - 17.44 |
| Beta | 1.59 |
| Analysts | Buy |
| Price Target | 27.00(+325.20%) |
| Earnings Date | Nov 4, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ACET
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ACET stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ACET holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ACET's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ACET Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ACET Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ACET patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ACET from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ACET
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $2.12M |
| VXFVanguard Extended Market ETF | $860.53K |
| IWCiShares Micro-Cap ETF | $194.07K |
| DFMCU.S. Micro Cap Portfolio ETF | $143.29K |
| DFASDimensional - US Small Cap ETF | $132.99K |
| AVSCAvantis U.S. Small Cap Equity ETF | $54.57K |
Estimated from each fund’s disclosed top holdings × AUM
ACET Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ACET’s recent data — informational, not investment advice